Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis

Blood Adv. 2020 Apr 14;4(7):1383-1387. doi: 10.1182/bloodadvances.2020001497.

Authors

Romain Lévy^{1

2}, Mathieu Fusaro^{1

3}, Frédéric Guerin¹, Ahmed Chetouani⁴, Despina Moshous^{1

2}, Alain Fischer^{1

2

5}, Geneviève de Saint Basile^{1

3}, Fernando E Sepulveda^{1

6}, Bénédicte Neven^{1

2}

Affiliations

¹ Imagine Institute, Université de Paris, INSERM U1163, Paris, France.
² Unité d'Immuno-Hematologie et Rhumatologie, Département de Pédiatrie, and.
³ Centre d'Etude des Deficits Immunitaires, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁴ Médecine Nucléaire, Groupe Hospitalier Nord-Essone, Orsay, France.
⁵ Collège de France, Paris, France; and.
⁶ Centre National de la Recherche Scientifique, Paris, France.

Abstract

First evidence of ruxolitinib efficacy for subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis.
Supporting rationale for ruxolitinib use, not more aggressive treatment, in this context, questioning this condition’s neoplastic nature.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Lymphohistiocytosis, Hemophagocytic* / drug therapy
Lymphoma, T-Cell* / drug therapy
Nitriles
Panniculitis* / drug therapy
Pyrazoles
Pyrimidines

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib

Supplementary concepts

Subcutaneous panniculitis-like T-cell lymphoma